Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Darbà J, Kaskens L, Sánchez-de la Rosa R J Med Econ. 2014 Mar; 17(3):215-22. PMID: 24494728. Abstract CommentRecommendBookmarkWatch